KKR & Co. completed its $5.89 billion acquisition of Integer Holdings in August, the month's largest private equity transaction and a data point that isolates healthcare as the sector drawing capital while broader PE activity retreats. The medical device manufacturer, which produces components for cardiac rhythm management and neuromodulation systems, moved from public to private ownership without fanfare. The deal closed in a month when global PE transaction volume fell 18% sequentially.
Healthcare accounted for 34% of August PE commitments by dollar volume, up from 22% in July and 19% in the second quarter. KKR's Integer purchase represented nearly half that monthly total. The firm paid a 27% premium to Integer's 30-day VWAP at announcement in late Q2, pricing the business at roughly 14.2x trailing EBITDA. Integer's revenue base is 68% recurring through long-term supply agreements with Medtronic, Abbott, and Boston Scientific. The company manufactures battery systems, lead technologies, and enclosures that sit inside implanted devices. KKR inherits $847 million in trailing twelve-month revenue and operating margins near 21%, both figures that held flat through the Federal Reserve's tightening cycle.
The timing reflects capital allocation under constraint. Broader PE dealmaking compressed as exit multiples lagged entry prices from 2021-2022 vintage funds. August saw $43 billion in announced PE transactions globally, the lowest monthly figure since December 2023. Healthcare deals, by contrast, maintained velocity. Six of the month's ten largest PE transactions targeted medical technology, diagnostics, or provider networks. Allocators are paying for duration and reimbursement visibility. Integer's customer base is concentrated but contractually locked. Device manufacturers don't switch component suppliers mid-product cycle. Revenue attrition risk is structural, not cyclical. That profile commands premium multiples when credit spreads are wide and refinancing windows are narrow.
The sector preference has second-order effects on fundraising and fee structures. Healthcare-focused PE funds raised $38 billion in the first eight months of 2024, already exceeding full-year 2023 totals. Limited partners are directing capital toward teams with regulatory expertise and clinical diligence capabilities. KKR's health sciences portfolio now holds nineteen platform investments, including Envision Healthcare, Cotiviti, and PetVet Care Centers. The firm's latest flagship fund, announced in June, allocated $8 billion of its $21.5 billion target to healthcare and life sciences. That allocation share is up from 18% in its prior fund. The move pressures generalist mega-funds to either build specialist teams or cede deal flow to vertical-focused competitors.
Operators should track two follow-on events. First, Integer's integration with KKR's existing med-tech holdings will clarify whether the firm is building a components rollup or positioning for a strategic exit to a larger device OEM within 24-36 months. Second, watch Cardinal Health and Owens & Minor for similar take-private interest in Q4. Both trade at depressed multiples relative to contract revenue bases. Limited partners should note that healthcare PE multiples are now 2.1x higher than industrial buyouts on a median EV/EBITDA basis, the widest spread since 2017. That gap persists because reimbursement-linked cash flows reprice slower than commodity-exposed businesses.
Integer's component backlog extends through Q2 2027. KKR inherits $1.4 billion in signed supply agreements that weren't contingent on the transaction closing.